Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.

Joshua D Frenster, Michael Kader, Scott Kamen, James Sun, Luis Chiriboga, Jonathan Serrano, Devin Bready, Danielle Golub, Niklas Ravn-Boess, Gabriele Stephan, Andrew S Chi, Sylvia C Kurz, Rajan Jain, Christopher Y Park, David Fenyo, Ines Liebscher, Torsten Schöneberg, Giselle Wiggin, Robert Newman, Matt Barnes, John K Dickson, Douglas J MacNeil, Xinyan Huang, Nadim Shohdy, Matija Snuderl, David Zagzag, Dimitris G Placantonakis

Neuro-oncology advances 2020 Jan-Dec

filter terms:

Glioma is a family of primary brain malignancies with limited treatment options and in need of novel therapies. We previously demonstrated that the adhesion G protein-coupled receptor GPR133 (ADGRD1) is necessary for tumor growth in adult glioblastoma, the most advanced malignancy within the glioma family. However, the expression pattern of GPR133 in other types of adult glioma is unknown. We used immunohistochemistry in tumor specimens and non-neoplastic cadaveric brain tissue to profile GPR133 expression in adult gliomas. We show that GPR133 expression increases as a function of WHO grade and peaks in glioblastoma, where all tumors ubiquitously express it. Importantly, GPR133 is expressed within the tumor bulk, as well as in the brain-infiltrating tumor margin. Furthermore, GPR133 is expressed in both isocitrate dehydrogenase (IDH) wild-type and mutant gliomas, albeit at higher levels in IDH wild-type tumors. The fact that GPR133 is absent from non-neoplastic brain tissue but de novo expressed in glioma suggests that it may be exploited therapeutically. © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Citation

PMID: 32642706

View Full Text